ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1432

Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions

Lihi Eder1, Sanjana Tarannum2, Kathleen Bush3, Sarah Cohen4, Charlene Compher4, Helen Emanoilidis2, Sarah Gillespie3, Dafna Gladman5, Vinod Chandran6, Jose Scher7 and Alexis R Ogdie4, 1Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 2Women's College Hospital, Toronto, ON, Canada, 3Division of Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, 4University of Pennsylvania, Philadelphia, PA, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 6Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, 7New York University School of Medicine, New York, NY

Meeting: ACR Convergence 2023

Keywords: diet, Psoriatic arthritis, Qualitative Research, Randomized Trial, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Dietary Interventions in psoriatic arthritis (DIPSA) is a randomized controlled trial (RCT) assessing the efficacy of dietary modifications in patients with psoriatic arthritis (PsA). Ideally, the design of an adjunct therapy trial and the intervention itself should engage patients in a positive experience. We aimed to describe patients’ experience participating in a dietary RCT in a rheumatology setting.

Methods: DIPSA (NCT04180904) compares the efficacy of the Mediterranean diet and DASH-low caloric diet as adjunct therapy to the standard of care in PsA. Patients with moderately active PsA (DAPSA > 10) who were overweight or obese (BMI 25-40) were enrolled into the trial for 24 weeks. The trial design is shown in Figure 1. At the end of the trial, participants underwent a semi-structured interview regarding their participation including challenges faced, positive aspects of the trial, and recommendations for a future intervention and/or trial. Interviews lasted 20-30 min and were carried out by trained research coordinators. The interviews of first 50 participants who completed the trial (out of intended 90) were analyzed using modified grounded theory by two research coordinators with input from the two PIs.

Results: The mean age of the participants was 54.8 years (SD 12.3 years) and 66% were females. Key themes identified included the benefit of increased wellness from healthy diet, structured intervention, support from dietitian and other staff, self-awareness, barriers to dietary changes, and other lifestyle changes (Figure 2). The themes, subthemes and a few representative quotes are included in Table 1. Patients found advice regarding healthy eating habits, setting personal goals, incorporating or avoiding particular food items in the diet to be beneficial for their overall health and well-being. However, most wished for a well-organized and structured diet in the form of recipes, menus, or a booklet. Support from the staff, phone calls from a dietitian and daily text messages motivated participants to adhere to the diet. Participants became more cognizant of the effect of diet on their pain and arthritis which led to higher confidence in controlling pain through dietary modification. Our study identified some important barriers to dietary change in PsA. Psychological barriers included reluctance to change the diet because of taste and habit, and difficulty adhering during times of stress and fatigue. Social issues arose when eating out, traveling or dining with others. Other barriers to healthy eating were related to time constraints and affordability. Finally, participants expressed a desire to continue beneficial dietary changes as well as to commit to other healthy lifestyle choices, e.g., increased physical activity, mindfulness and meditation.

Conclusion: Patients with PsA found the DIPSA interventions to be feasible and valuable. Support from a multidisciplinary team, especially dietitian advice, was deemed crucial. Psychosocial barriers, cost and time constraints prevent patients from implementing healthy dietary changes. Finally, focusing on dietary change had carryover, helping patients to make healthy choices in other aspects of life.

Supporting image 1

Figure 1: DIPSA study design and procedures

Supporting image 2

Figure 2: Summary of themes and subthemes that were identified in the interviews of study participants


Disclosures: L. Eder: AbbVie, 2, 5, Eli Lilly, 2, 5, Fresenius Kabi, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Sandoz, 5, UCB, 2, 5; S. Tarannum: None; K. Bush: None; S. Cohen: None; C. Compher: None; H. Emanoilidis: None; S. Gillespie: None; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, Bristol Myers Squibb, 2, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, Gilead Sciences, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, UCB, 2, 5; V. Chandran: AbbVie, 1, 5, 6, Amgen, 1, 5, 6, AstraZeneca, 3, Bristol-Myers Squibb (BMS), 1, 6, Eli Lilly, 1, 5, 6, Janssen, 1, 6, Novartis, 1, 1, 6, UCB, 1, 2; J. Scher: AbbVie, 2, Janssen, 2, 5, Novartis, 5, Pfizer, 2, 5, Sanofi, 2, UCB, 2; A. Ogdie: AbbVie/Abbott, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb(BMS), 2, Celgene, 2, CorEvitas, 2, Eli Lilly, 2, Gilead, 2, GSK, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Takeda, 2, UCB, 2.

To cite this abstract in AMA style:

Eder L, Tarannum S, Bush K, Cohen S, Compher C, Emanoilidis H, Gillespie S, Gladman D, Chandran V, Scher J, Ogdie A. Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/experiences-and-perspectives-of-patients-with-psoriatic-arthritis-participating-in-a-randomized-controlled-trial-of-dietary-interventions/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/experiences-and-perspectives-of-patients-with-psoriatic-arthritis-participating-in-a-randomized-controlled-trial-of-dietary-interventions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology